TABLE 1.
Baseline characteristics
| Parameter | Value for the groupa |
P | |||
|---|---|---|---|---|---|
| LR-BAC (n = 109) | LR-BAT (n = 109) | HR-BAC (n = 106) | HR-BAT (n = 107) | ||
| Gender | |||||
| Male | 64 | 75 | 67 | 64 | 0.4123 |
| Female | 45 | 34 | 39 | 43 | |
| Age (yr [range]) | 38.9 ± 12.01 (20–65) | 41.8 ± 13.31 (18–70) | 38.8 ± 12.81 (18–69) | 41.4 ± 13.35 (18–69) | 0.1895 |
| Smoking status | |||||
| Former | 1 (0.9) | 2 (1.8) | 0 | 0 | 0.2980 |
| Current | 31 (28.4) | 39 (35.8) | 34 (32.1) | 43 (40.2) | 0.3021 |
| Alcohol use | 0.2572 | ||||
| Never | 66 (60.6) | 68 (62.4) | 61 (57.5) | 68 (63.6) | |
| Sometimes | 40 (36.7) | 39 (35.8) | 36 (34.0) | 32 (29.9) | |
| Often | 3 (2.8) | 2 (1.8) | 9 (8.5) | 7 (6.5) | |
| Drug use history | |||||
| Clarithromycin | 5 (4.6) | 2 (1.8) | 0 | 2 (1.9) | 0.1300 |
| Amoxicillin | 47 (43.1) | 45 (41.3) | 45 (42.5) | 45 (42.1) | 0.9943 |
| Tetracycline | 1 (0.9) | 4 (3.7) | 5 (4.7) | 0 | 0.0703 |
| Bismuth | 2 (1.8) | 5 (4.6) | 5 (4.7) | 4 (3.7) | 0.6576 |
| Peptic ulcer history | 7 (6.4) | 14 (12.8) | 5 (4.7) | 9 (8.4) | 0.1486 |
| Upper gastrointestinal bleeding history | 1 (0.9) | 4 (3.7) | 3 (2.8) | 1 (0.9) | 0.3846 |
| Chronic gastritis history | 12 (11.0) | 13 (11.9) | 10 (9.4) | 7 (6.5) | 0.5626 |
| Family history of gastric cancer | 2 (1.8) | 1 (0.9) | 0 | 4 (3.7) | 0.1636 |
a
Unless otherwise stated, values are number of patients (percentage of patients). LR-BAC group, rabeprazole at 10 mg b.i.d. plus bismuth, amoxicillin, and clarithromycin; LR-BAT group, rabeprazole at 10 mg b.i.d. plus bismuth, amoxicillin, and tetracycline; HR-BAC group, rabeprazole at 20 mg b.i.d. plus bismuth, amoxicillin, and clarithromycin; HR-BAT group, rabeprazole at 10 mg b.i.d. plus bismuth, amoxicillin, and tetracycline.